Publications

The glucocorticoid mometasone furoate is a novel FXR ligand that decreases inflammatory but not metabolic gene expression.
Bijsmans IT, Guercini C, Ramos Pittol JM, Omta W, Milona A, Lelieveld D, Egan DA, Pellicciari R, Gioiello A, van Mil SW.
Sci Rep. 2015 Sep 15;5:14086.

Scaffold hopping approach on the route to selective tankyrase inhibitors.
Liscio P, Carotti A, Asciutti S, Ferri M, Pires MM, Valloscuro S, Ziff J, Clark NR, Macchiarulo A, Aaronson SA, Pellicciari R, Camaioni E.
Eur J Med Chem. 2014 Oct 5;87C:611-623.

Investigating the allosteric reverse signalling of PARP inhibitors with microsecond molecular dynamic simulations and fluorescence anisotropy.
Marchand JR, Carotti A, Passeri D, Filipponi P, Liscio P, Camaioni E, Pellicciari R, Gioiello A, Macchiarulo A.
Biochim Biophys Acta. 2014 Oct;1844(10):1765-72.

Synthesis of atypical bile acids for use as investigative tools for the genetic defect of 3β-hydroxy-Δ5-C27-steroid oxidoreductase deficiency.
Gioiello A, Cerra B, Zhang W, Vallerini GP, Costantino G, Franco FD, Passeri D, Pellicciari R, Setchell KD.
J Steroid Biochem Mol Biol. 2014 Jun 19;144PB:348-360.

Probing the Binding Site of Bile Acids in TGR5.
Macchiarulo A, Gioiello A, Thomas C, Pols TW, Nuti R, Ferrari C, Giacchè N, De Franco F, Pruzanski M, Auwerx J, Schoonjans K, Pellicciari R.
ACS Med Chem Lett. 2013 Oct 15;4(12):1158-62.

Semisynthetic bile acid FXR and TGR5 agonists: physicochemical properties, pharmacokinetics, and metabolism in the rat.
Roda A, Pellicciari R, Gioiello A, Neri F, Camborata C, Passeri D, De Franco F, Spinozzi S, Colliva C, Adorini L, Montagnani M, Aldini R.
J Pharmacol Exp Ther. 2014 Jul;350(1):56-68.

Synthesis and quantitative structure-property relationships of side chain-modified hyodeoxycholic acid derivatives.
Sabbatini P, Filipponi P, Sardella R, Natalini B, Nuti R, Macchiarulo A, Pellicciari R, Gioiello A.
Molecules. 2013 Aug 30;18(9):10497-513.